RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/31954274http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/31954274http://www.w3.org/2000/01/rdf-schema#comment"The interaction between CD155 and its high-affinity ligand TIGIT is being increasingly investigated in various solid tumors. However, the prognostic significance of CD155 and TIGIT in lung adenocarcinoma (LUAD) remains unclear. In this study, immunohistochemistry was applied in 334 LUAD cases to evaluate the expression of CD155 and TIGIT. Western blotting was conducted in 5 paired primary LUAD and adjacent normal lung tissues. Our results reveal that CD155 and TIGIT are overexpressed in LUAD tissues and that aberrant overexpression is closely correlated with poor clinical outcomes (P < 0.01). The multivariate model also shows that CD155 expression is an independent risk factor for LUAD (RR, 1.34; P = 0.036). Moreover, patients expressing high CD155 and TIGIT simultaneously presented shorter overall survival (OS) (P < 0.01) and progression-free survival (PFS) (P < 0.01). These findings suggest that CD155 and TIGIT can make up a prognosticating tool to predict clinical outcomes, thereby contributing to personalized medical care in LUAD."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.org/dc/terms/identifier"doi:10.1016/j.intimp.2020.106198"xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Chen L."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Chen Y."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Jiang W."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Jiang N."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Ke Z."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Lei Y."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Luo J."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Sun Y."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Tang K."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Cui J."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Cui Y."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Kuang Y."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/author"Chen Y.'"xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/name"Int Immunopharmacol"xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/pages"106198"xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/title"Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)."xsd:string
http://purl.uniprot.org/citations/31954274http://purl.uniprot.org/core/volume"80"xsd:string
http://purl.uniprot.org/citations/31954274http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/31954274
http://purl.uniprot.org/citations/31954274http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/31954274
http://purl.uniprot.org/uniprot/#_A0A0A0MSA9-mappedCitation-31954274http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31954274
http://purl.uniprot.org/uniprot/#_A0A0C4DG49-mappedCitation-31954274http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31954274